Novel Biomarkers for Heart Disease
Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2020 |
| Language: | English |
| Physical Description: | 1 electronic resource (420 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 05676nam-a2201669z--4500 | ||
|---|---|---|---|
| 001 | 993546372104498 | ||
| 005 | 20231214133607.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202105s2020 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5400000000044145 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/69451 | ||
| 035 | |a (EXLCZ)995400000000044145 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Lichtenauer, Michael |4 edt | |
| 245 | 1 | 0 | |a Novel Biomarkers for Heart Disease |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 electronic resource (420 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a diet quality | ||
| 653 | |a ceramides | ||
| 653 | |a obesity | ||
| 653 | |a cardiovascular risk | ||
| 653 | |a healthy eating index | ||
| 653 | |a carbohydrate antigen-125 | ||
| 653 | |a heart failure | ||
| 653 | |a inflammatory marker | ||
| 653 | |a older women | ||
| 653 | |a biomarker | ||
| 653 | |a cardiometabolic disease | ||
| 653 | |a epicardial adipose tissue | ||
| 653 | |a epicardial fat | ||
| 653 | |a epicardial fat volume | ||
| 653 | |a microRNA | ||
| 653 | |a thyroid-stimulating hormone | ||
| 653 | |a cardiometabolic risks | ||
| 653 | |a metabolic syndrome | ||
| 653 | |a hypertension | ||
| 653 | |a very low-density lipoprotein | ||
| 653 | |a STIM1 | ||
| 653 | |a SOCE | ||
| 653 | |a atrial myopathy | ||
| 653 | |a atrial fibrillation | ||
| 653 | |a ejection fraction | ||
| 653 | |a soluble urokinase-type plasminogen activator receptor (suPAR) | ||
| 653 | |a growth differentiation factor 15 (GDF-15) | ||
| 653 | |a heart-type fatty acid-binding protein (H-FABP) | ||
| 653 | |a soluble suppression of tumorigenicity 2 (sST2) | ||
| 653 | |a acute myocardial infarction | ||
| 653 | |a biomarkers | ||
| 653 | |a catestatin | ||
| 653 | |a coronary artery disease | ||
| 653 | |a heart failure decompensation | ||
| 653 | |a left ventricular ejection fraction | ||
| 653 | |a troponin | ||
| 653 | |a NT-proBNP | ||
| 653 | |a NYHA functional class | ||
| 653 | |a GDF-15 | ||
| 653 | |a cardiovascular surgery | ||
| 653 | |a operative risk | ||
| 653 | |a muscle wasting | ||
| 653 | |a sarcopenia | ||
| 653 | |a renal dysfunction | ||
| 653 | |a chronic kidney disease | ||
| 653 | |a aortic disease | ||
| 653 | |a aneurysm | ||
| 653 | |a miRNA | ||
| 653 | |a TGF-β pathway | ||
| 653 | |a KLF4 | ||
| 653 | |a synthetic phenotype | ||
| 653 | |a aortic regurgitation | ||
| 653 | |a echocardiography | ||
| 653 | |a magnetic resonance imaging | ||
| 653 | |a vena contracta area | ||
| 653 | |a longitudinal strain | ||
| 653 | |a T1 mapping | ||
| 653 | |a GDF8 | ||
| 653 | |a myostatin | ||
| 653 | |a AMI | ||
| 653 | |a ceruloplasmin | ||
| 653 | |a H-FABP | ||
| 653 | |a heart-type fatty acid-binding protein | ||
| 653 | |a FABP3 | ||
| 653 | |a fatty acid-binding protein 3 | ||
| 653 | |a HF | ||
| 653 | |a cardiac biomarkers | ||
| 653 | |a cardiac magnetic resonance imaging | ||
| 653 | |a left ventricular systolic function | ||
| 653 | |a magnetic resonance spectroscopy | ||
| 653 | |a myocardial triglyceride content | ||
| 653 | |a cell adhesion molecule | ||
| 653 | |a repeated measurements | ||
| 653 | |a pregnancy-associated plasma protein-A | ||
| 653 | |a cohort studies | ||
| 653 | |a cardiovascular diseases | ||
| 653 | |a mitochondrial dysfunction | ||
| 653 | |a circulating cells | ||
| 653 | |a PBMCS | ||
| 653 | |a platelets | ||
| 653 | |a oxidative stress | ||
| 653 | |a reactive oxygen species (ROS) | ||
| 653 | |a mitochondrial DNA (mtDNA) | ||
| 653 | |a herat failure | ||
| 653 | |a liver-type fatty-acid-binding protein | ||
| 653 | |a long-term outcomes | ||
| 653 | |a cardiac intensive care units | ||
| 653 | |a acute kidney injury | ||
| 653 | |a myocardial infarction | ||
| 653 | |a STEMI | ||
| 653 | |a cardiovascular events | ||
| 653 | |a cardiovascular death | ||
| 653 | |a risk stratification | ||
| 653 | |a sST2 | ||
| 653 | |a Pentraxin-3 | ||
| 653 | |a sudden cardiac death | ||
| 653 | |a ventricular arrhythmia | ||
| 653 | |a ventricular tachycardia | ||
| 653 | |a chronic heart failure | ||
| 653 | |a saliva | ||
| 653 | |a salivary biomarkers | ||
| 653 | |a CKD | ||
| 653 | |a CVD | ||
| 653 | |a PPCI | ||
| 653 | |a left ventricular adverse remodelling | ||
| 653 | |a circulating miRNAs | ||
| 653 | |a NAFLD | ||
| 653 | |a Framingham risk score | ||
| 653 | |a risk prediction | ||
| 653 | |a secondary prevention | ||
| 653 | |a primary prevention | ||
| 653 | |a NAFLD fibrosis score | ||
| 653 | |a HFpEF | ||
| 653 | |a HFrEF | ||
| 653 | |a suPAR | ||
| 776 | |z 3-03943-883-2 | ||
| 776 | |z 3-03943-884-0 | ||
| 700 | 1 | |a Lichtenauer, Michael |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:58:47 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338224220004498&Force_direct=true |Z 5338224220004498 |b Available |8 5338224220004498 | ||